Drugs Containing Excipient (Inactive Ingredient) HYALURONATE SODIUM

« Back to Dashboard

Branded drugs containing HYALURONATE SODIUM excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ALTRENO	tretinoin	0187-0005	HYALURONATE SODIUM
PharmaDerm a division of Fougera Pharmaceuticals Inc	SOLARAZE	diclofenac sodium	10337-803	HYALURONATE SODIUM
PharmaDerm a division of Fougera Pharmaceuticals Inc	SOLARAZE	diclofenac sodium	10337-844	HYALURONATE SODIUM
Bausch Health US LLC	ATRALIN	tretinoin	13548-070	HYALURONATE SODIUM
Orasis Pharmaceuticals Inc	QLOSI	pilocarpine hydrochloride	83661-018	HYALURONATE SODIUM

Generic drugs containing HYALURONATE SODIUM excipient

Company	Ingredient	NDC	Excipient
Bausch Health US LLC	tretinoin	0187-0005	HYALURONATE SODIUM
Mylan Pharmaceuticals Inc	tretinoin	0378-8090	HYALURONATE SODIUM
Actavis Pharma Inc	diclofenac sodium	0472-1783	HYALURONATE SODIUM
PharmaDerm a division of Fougera Pharmaceuticals Inc	diclofenac sodium	10337-803	HYALURONATE SODIUM
PharmaDerm a division of Fougera Pharmaceuticals Inc	diclofenac sodium	10337-844	HYALURONATE SODIUM

Sodium Hyaluronate Pharmaceutical Excipient Market: Dynamics, Financial Trajectory, Patents, and Competitive Landscape

Last updated: September 24, 2026

Sodium hyaluronate is a regulated, specification-driven pharmaceutical excipient used in ophthalmic, injectable, topical, nasal, wound-care, and controlled-delivery formulations. Its commercial outlook is favorable, but value growth is shifting from commodity material toward sterile, low-endotoxin, high-purity, molecular-weight-controlled grades supported by regulatory documentation.

The market has no single authoritative global revenue figure because industry reports combine pharmaceutical excipient sales with cosmetic, medical-device, injectable aesthetic, and dietary-supplement applications. The pharmaceutical-grade segment is smaller than the total hyaluronate market but has higher pricing, stronger customer qualification requirements, and greater switching costs.

What is sodium hyaluronate and how is it used as a pharmaceutical excipient?

Sodium hyaluronate is the sodium salt of hyaluronic acid, a naturally occurring glycosaminoglycan. Its CAS Registry Number is 9067-32-7. In pharmaceutical formulations, its commercial value depends on molecular weight, concentration, source, purification profile, endotoxin level, residual protein, bioburden, viscosity, and sterility.

Common excipient functions include:

Function	Representative pharmaceutical use
Viscosity modifier	Ophthalmic solutions, nasal sprays, oral liquids
Lubricant	Artificial tears and mucosal formulations
Mucoadhesive	Nasal, ocular, buccal, and vaginal delivery
Moisture-retention agent	Wound-care and topical products
Controlled-release matrix	Injectable and local-delivery systems
Tissue-compatible carrier	Ophthalmic and parenteral formulations
Stabilizer or rheology modifier	Biologic and peptide formulations under development

Sodium hyaluronate is also used in products where it is the active pharmaceutical ingredient, device component, or constituent of a combination product. That distinction affects regulatory status, patent exposure, and pricing.

Pharmaceutical excipient buyers normally purchase material by grade rather than by chemical identity alone. A buyer may specify a molecular-weight range, animal-free fermentation, endotoxin threshold, sterility assurance level, viscosity at defined concentration, and compendial compliance.

What are the main pharmaceutical applications for sodium hyaluronate?

Ophthalmic products are the most established pharmaceutical application. Sodium hyaluronate is used in artificial tears, surgical ophthalmic viscoelastic devices, and ophthalmic formulations designed to improve retention on the ocular surface. In many ophthalmic products, it is marketed as an active ingredient rather than only as an inactive excipient.

Injectable and parenteral applications generate higher unit prices but require more extensive quality controls. These include local-delivery systems, tissue engineering, intra-articular products, ophthalmic surgery, wound management, and combination products. Injectable grades require validated control of endotoxins, residual impurities, molecular-weight distribution, and microbial contamination.

Topical and mucosal applications include wound gels, nasal products, vaginal formulations, and dermatological preparations. These products typically have lower technical barriers than sterile injectables but remain sensitive to viscosity, purity, and microbial specifications.

The cosmetic and aesthetic markets are larger volume drivers in many supply chains. Dermal fillers and skin-care products consume substantial quantities of hyaluronate, although they do not represent pharmaceutical excipient demand. Cosmetic demand can improve manufacturing scale while also creating price competition for standard grades.

How large is the sodium hyaluronate pharmaceutical excipient market?

Published market estimates should be treated cautiously. Many commercial reports aggregate:

• Pharmaceutical excipients
• Ophthalmic active ingredients
• Dermal fillers
• Medical devices
• Cosmetics
• Nutraceuticals
• Veterinary products
• Hyaluronic acid used in tissue engineering

As a result, reported global hyaluronic acid market figures are not interchangeable with revenue for pharmaceutical-grade sodium hyaluronate.

A more useful market structure is:

Segment	Relative volume	Relative price	Qualification burden	Growth profile
Standard cosmetic grade	High	Low	Low to moderate	Moderate
Oral and topical pharmaceutical grade	Moderate	Moderate	Moderate	Moderate
Ophthalmic grade	Moderate	Moderate to high	High	Stable to moderate
Sterile injectable grade	Lower	High	Very high	Above average
Crosslinked or modified hyaluronate	Lower	Very high	Very high	High but application-specific
Research and regenerative medicine grade	Low	High	High	Uneven, development-driven

The pharmaceutical excipient segment should grow faster in value than in volume because customers are moving toward higher-purity and application-specific grades. Unit economics improve when a supplier can sell validated sterile material, customized molecular-weight distributions, or formulation support rather than bulk powder.

What is driving demand for pharmaceutical-grade sodium hyaluronate?

Growth in ophthalmic and mucosal products

Ophthalmic formulations remain a stable demand base. Aging populations, dry-eye prevalence, increased screen exposure, and expansion of preservative-free formulations support demand for viscosity-modifying and lubricating polymers. Preservative-free multidose systems may require more demanding compatibility and microbial-control specifications.

Expansion of injectable and regenerative applications

Sodium hyaluronate is used in drug delivery, tissue scaffolds, wound care, and local-release systems. These applications are development-intensive and can create higher margins, although commercialization rates are lower than in established ophthalmic products.

Shift toward fermentation and animal-free sourcing

Pharmaceutical customers increasingly prefer bacterial fermentation over extraction from rooster combs or other animal-derived sources. Fermentation supports more consistent supply, traceability, and animal-free positioning. It does not eliminate the need to control host-cell residues, protein, nucleic acids, endotoxin, and process-related impurities.

Regulatory pressure on excipient quality

The FDA Inactive Ingredient Database, United States Pharmacopeia-National Formulary, European Pharmacopoeia, and customer-specific quality agreements influence material selection. Compendial status reduces qualification friction but does not replace product-specific compatibility and process validation (U.S. Pharmacopeia, 2024; U.S. Food and Drug Administration, 2024a).

Demand for molecular-weight control

Molecular weight affects viscosity, residence time, tissue interaction, injectability, and release behavior. Suppliers with narrow and reproducible specifications can command higher prices than suppliers selling broad-range material.

Who are the leading sodium hyaluronate manufacturers?

The competitive field includes diversified biotechnology companies, specialty excipient manufacturers, pharmaceutical suppliers, and medical-device businesses.

Company	Primary competitive position	Relevant strengths
Bloomage Biotechnology	Large-scale hyaluronic acid producer	Fermentation scale, broad molecular-weight portfolio, global distribution
HTL Biotechnology	Pharmaceutical and medical-grade hyaluronate supplier	High-purity grades, injectable and biomedical applications
Contipro	Specialty hyaluronate and biomedical materials	Research collaboration, pharmaceutical and regenerative applications
Kewpie Corporation	Fermentation-based hyaluronate producer	Established production technology and pharmaceutical materials
Seikagaku Corporation	Pharmaceutical and medical applications	Hyaluronate products, injectable and ophthalmic expertise
Fidia Farmaceutici	Hyaluronate-based pharmaceutical and medical products	Formulation, injectable products, clinical and commercial applications
Lifecore Biomedical	Contract development and manufacturing	Sterile hyaluronate processing and combination-product support
Evonik and other excipient specialists	Formulation and drug-delivery platforms	Customer integration and delivery-system capabilities

Not all companies disclose sodium hyaluronate revenue separately. Public-company reporting generally combines hyaluronate with broader bioactive materials, pharmaceutical products, medical devices, or contract manufacturing. The absence of segment disclosure makes supplier-level market-share calculations unreliable.

How does the sodium hyaluronate market make money?

The value chain has four economic layers:

1. Fermentation or biological production.
2. Purification, precipitation, drying, and molecular-weight control.
3. Sterile finishing, packaging, and quality release.
4. Formulation, regulatory support, and contract development.

Commodity powder has the lowest margin. Purified pharmaceutical material has higher pricing. Sterile injectable material and customer-specific grades have the strongest margin potential because they require validated processes and long customer qualification cycles.

Key cost drivers include:

• Fermentation yield
• Downstream purification efficiency
• Energy and water consumption
• Sterile processing
• Endotoxin removal
• Analytical testing
• Batch failure and reprocessing rates
• Regulatory documentation
• Cold-chain or controlled-storage requirements
• Customer audits and site qualification

Manufacturing scale can reduce cost per kilogram, but scale alone does not guarantee pharmaceutical competitiveness. A large cosmetic producer may lack the sterile operations, documentation, or change-control discipline required by a regulated pharmaceutical customer.

What is the financial trajectory for sodium hyaluronate suppliers?

The financial trajectory is likely to divide into three tiers.

Commodity and standard-grade suppliers

These suppliers face pricing pressure from increased fermentation capacity, Chinese production expansion, and competition from cosmetic-grade material. Revenue can grow with volume while margins remain flat or decline.

Pharmaceutical-grade suppliers

These companies have stronger pricing power because customers qualify specific sites, processes, and grades. Growth is supported by ophthalmic products, sterile formulations, and supply-chain diversification. Contract durations and technical service can improve retention.

Specialty and platform suppliers

Suppliers offering crosslinked hyaluronate, injectable delivery systems, regenerative-medicine materials, or formulation development can achieve the highest gross margins. Their revenue is less predictable because it depends on customer development programs and regulatory approvals.

A practical financial model should separate:

Revenue driver	Margin effect	Risk
Volume growth	Positive but limited	Capacity oversupply
Grade upgrade	Strongly positive	Customer qualification delays
Sterile finishing	Positive	Quality and compliance costs
Custom molecular weight	Positive	Small production runs
Crosslinked derivatives	Very positive	Patent and clinical risk
Contract development	Positive	Project cancellation
Cosmetic exposure	Variable	Price competition

The best-positioned suppliers will increase the proportion of revenue from sterile, injectable, ophthalmic, and customized grades. Suppliers dependent on bulk cosmetic and nutraceutical demand face more volatile pricing.

What patents protect sodium hyaluronate products?

There is no single foundational patent that broadly controls sodium hyaluronate as a chemical substance. The underlying polymer and basic production concepts are old. Commercial patent protection generally covers:

• Fermentation organisms and engineered strains
• Fermentation conditions
• Purification and endotoxin-removal methods
• Molecular-weight control
• Crosslinking chemistry
• Injectable formulations
• Ophthalmic formulations
• Sustained-release systems
• Combination products
• Tissue-engineering scaffolds
• Specific medical uses

Patent rights are usually directed to a process, formulation, derivative, or use rather than unmodified sodium hyaluronate itself. The enforceable scope depends on claim language, priority dates, prosecution history, jurisdiction, and whether the product uses crosslinked or chemically modified material.

A supplier’s intellectual-property position should be assessed across the following categories:

IP category	Typical protection period	Commercial relevance
Basic sodium hyaluronate composition	Often expired or weak	Low
Fermentation process	20 years from nonprovisional filing, subject to jurisdiction	Moderate
Purification process	20 years from filing	Moderate to high
Crosslinked derivative	20 years from filing	High
Drug-delivery formulation	20 years from filing	High
Manufacturing know-how	Potentially indefinite if secret	High
Analytical specifications	Usually not patent-protected	Customer qualification value

Patent searches should cover WIPO Patentscope, USPTO Patent Center, Espacenet, national registers, and litigation databases. Patent-family analysis is more important than counting documents because the same invention may appear in multiple jurisdictions.

When does sodium hyaluronate lose exclusivity?

Unmodified sodium hyaluronate generally does not have a single market-wide exclusivity date. It is a mature material with multiple suppliers and established pharmaceutical use.

Exclusivity is product-specific:

• A formulation patent may expire separately from a process patent.
• A crosslinked derivative may retain active patent protection after standard sodium hyaluronate becomes broadly available.
• A drug product may have Orange Book-listed patents even when its sodium hyaluronate excipient is unprotected.
• Regulatory exclusivity applies to the finished product, not to the excipient as a general chemical.
• Trade secrets involving fermentation and purification may continue after patents expire.

Patent term in the United States generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and jurisdiction-specific rules (U.S. Patent and Trademark Office, 2024).

What is the FDA regulatory and Orange Book status of sodium hyaluronate?

Sodium hyaluronate is listed in FDA’s Inactive Ingredient Database for certain routes and dosage forms, subject to the specific database entries and maximum potency information. An IID listing supports regulatory precedent but does not establish automatic approval for every route, concentration, molecular-weight range, or product type (U.S. Food and Drug Administration, 2024a).

Sodium hyaluronate itself is not an Orange Book-listed drug product. The Orange Book lists approved finished prescription drug products and relevant patent and exclusivity information, not excipients as standalone substances (U.S. Food and Drug Administration, 2024b).

Regulatory classification depends on use:

• As an excipient, it is assessed within the finished drug application.
• As an ophthalmic active ingredient, it is part of the drug’s active-ingredient review.
• In a medical device, it may be a constituent material.
• In an injectable aesthetic or orthopedic product, it may be regulated under a drug, device, biologic, or combination framework depending on the product and jurisdiction.
• In a biologic formulation, it requires compatibility and safety assessment within the biologics application.

Do Paragraph IV challenges or biosimilar risks affect sodium hyaluronate?

Paragraph IV litigation does not target sodium hyaluronate as a generic excipient. It applies when an ANDA applicant challenges patents listed for a reference drug in the Orange Book. A sodium hyaluronate-containing drug could face an ANDA challenge if the finished product is eligible for the abbreviated pathway and has listed patents.

Biosimilar risk is also limited. Sodium hyaluronate is a non-biologic polymer and is not itself subject to the biosimilar pathway. Risk arises indirectly when it is used in a biologic formulation, delivery system, or combination product. The relevant competitor would usually be a biosimilar or interchangeable biologic, not a biosimilar version of sodium hyaluronate.

What generic entry risks exist for sodium hyaluronate products?

Generic entry risk is highest for:

• Simple ophthalmic solutions
• Standard topical formulations
• Nonsterile products
• Products with broad and expired formulation claims
• Products using widely available molecular-weight grades

Risk is lower for:

• Sterile injectable products
• Crosslinked hyaluronate systems
• Combination products
• Products with complex delivery devices
• Formulations protected by manufacturing and use patents
• Products requiring extensive clinical or device-performance data

Generic competition can reduce demand for a branded finished product while increasing demand for pharmaceutical-grade raw material. The economic effect on excipient suppliers is therefore mixed.

What licensing deals and partnerships matter?

Licensing and partnership activity is concentrated in downstream applications rather than basic sodium hyaluronate powder. Common structures include:

• Long-term supply agreements
• Exclusive distribution by territory
• Contract development and manufacturing
• Co-development of injectable formulations
• Licensing of crosslinking or drug-loading technology
• Partnerships for regenerative medicine and tissue scaffolds
• Technology transfer for fermentation or sterile processing

Supplier agreements often include minimum purchase commitments, change-control restrictions, audit rights, dual-sourcing provisions, and regulatory-support obligations. These terms can create meaningful switching costs even when the chemical material is not patent-protected.

How does sodium hyaluronate compare with competing excipients?

Excipient	Main advantage	Main limitation	Relative competition
Sodium hyaluronate	Biocompatibility and mucoadhesion	Higher cost and variable molecular weight	Moderate
Carbomer	Strong viscosity and broad availability	Can have pH and ionic-strength limitations	High
Hydroxypropyl methylcellulose	Established ophthalmic and oral use	Less biologically interactive	High
Carboxymethylcellulose	Low cost and broad availability	Different rheology and retention profile	High
Chitosan	Mucoadhesion and bioactivity	Regulatory and source variability	Moderate
Poloxamers	Thermoresponsive and solubilizing properties	Different tissue-retention profile	Moderate
Polyethylene glycol	Broad formulation utility	Lower biological resemblance	Very high

Sodium hyaluronate competes successfully where biocompatibility, hydration, tissue residence, or mucoadhesion justify a premium. It is less competitive in cost-sensitive products where standard cellulose derivatives or synthetic polymers provide adequate performance.

What manufacturing and intellectual-property barriers protect suppliers?

The strongest barriers are operational rather than molecule-level patent rights. They include:

• Validated fermentation processes
• Consistent molecular-weight control
• Endotoxin and protein removal
• Sterile manufacturing
• Regulatory history
• Customer-specific specifications
• Qualified alternate suppliers
• Stability data
• Batch-to-batch analytical comparability
• Change-control discipline

A pharmaceutical customer may take 12 to 36 months to qualify a new supplier depending on the product, route, and regulatory filing status. That period creates practical protection even without broad patent coverage.

Geographic concentration remains relevant. China has significant production capacity, while Japanese, European, and North American suppliers retain advantages in regulated markets, technical documentation, sterile processing, and customer confidence. Buyers increasingly seek dual sourcing across regions to reduce disruption risk.

Key Takeaways

• Sodium hyaluronate is a mature but expanding pharmaceutical excipient and biomaterial.
• The highest-value demand is in sterile injectable, ophthalmic, molecular-weight-controlled, and customized grades.
• Published market-size estimates often overstate the pharmaceutical excipient segment by including cosmetics, fillers, devices, and supplements.
• Standard sodium hyaluronate has limited broad composition-patent protection; commercial IP is concentrated in processes, derivatives, formulations, and uses.
• The material itself has no standalone Orange Book exclusivity or biosimilar pathway.
• Paragraph IV risk applies only to eligible finished drug products containing sodium hyaluronate.
• Financial growth should come from grade upgrades, sterile processing, custom specifications, and downstream formulation services rather than bulk-volume expansion alone.
• Fermentation scale, purification quality, regulatory documentation, and customer qualification are the principal barriers to entry.
• Supplier margins are likely to diverge between commodity grades and specialty pharmaceutical platforms.
• The strongest competitive positions combine material supply with formulation development, sterile manufacturing, and regulatory support.

FAQs About Sodium Hyaluronate Pharmaceutical Excipient Economics

Is sodium hyaluronate a high-margin pharmaceutical excipient?

Standard powder is usually less profitable than sterile, injectable, crosslinked, or customer-specific grades. Margin depends more on qualification and processing requirements than on the chemical identity alone.

Can a company patent pharmaceutical-grade sodium hyaluronate?

A company generally cannot obtain broad new protection over the old, unmodified polymer. It may patent a manufacturing process, molecular-weight-control method, formulation, derivative, delivery system, or specific medical use.

Is sodium hyaluronate listed in the FDA Inactive Ingredient Database?

Yes, sodium hyaluronate has FDA IID entries for certain dosage forms and routes. The relevant entry must be matched against the proposed product’s route, concentration, dosage form, and molecular characteristics.

Does sodium hyaluronate require animal-free sourcing for pharmaceutical use?

Not universally. Animal-free fermentation is commercially preferred for many pharmaceutical applications because it improves traceability, consistency, and market acceptance. Product-specific regulatory and customer requirements determine whether it is mandatory.

What is the largest commercial risk for sodium hyaluronate suppliers?

The main risk is commoditization caused by excess fermentation capacity and price competition in standard grades. Suppliers reduce that risk by increasing sales of sterile, regulated, customized, and formulation-linked products.

References

1. European Medicines Agency. (2016). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. https://www.ema.europa.eu/

2. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Patent and Trademark Office. (2024). Patent term and adjustment information. https://www.uspto.gov/patents/laws/patent-term-adjustment

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

6. World Health Organization. (2022). WHO good manufacturing practices for pharmaceutical excipients. World Health Organization. https://www.who.int/